 Connection
Samer Al Hadidi to Neoplasms
This is a "connection" page, showing publications Samer Al Hadidi has written about Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.782 |
|
|
|
-
Abusamak AA, Abusamak M, Al-Abbadi M, Rayyan A, Oran O, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Cliff ERS, Al Hadidi S. Use of subjective minimizing language at hematology and oncology conferences: A systematic review. J Cancer Policy. 2024 Mar; 39:100461.
Score: 0.498
-
Al Hadidi S. The Use of Modified Surrogate End Points in Cancer Clinical Trials. Cancer Invest. 2022 01; 40(1):14-16.
Score: 0.433
-
Awidi M, Al Hadidi S. Participation of Black Americans in Cancer Clinical Trials: Current Challenges and Proposed Solutions. JCO Oncol Pract. 2021 05; 17(5):265-271.
Score: 0.416
-
Al Hadidi S. Aspirin and Cancer Risk. JAMA Oncol. 2016 10 01; 2(10):1371-1372.
Score: 0.303
-
Al Hadidi S, Mims M, Miller-Chism CN, Kamble R. Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs. Ann Intern Med. 2020 08 18; 173(4):320-322.
Score: 0.098
-
Patel T, Chen C, Al Hadidi S, Kadry Y, Sridhara R, Purcell E, Wisch L, Retzlaff J, Foti M, Pazdur R, Kluetz P, Gao J. Reflections and Roadmaps: Career Development beyond the FDA-AACR Oncology Educational Fellowship. Clin Cancer Res. 2024 Aug 01; 30(15):3144-3146.
Score: 0.033
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|